Paxlovid is Australia's first-line COVID antiviral but Lagevrio also prevents severe disease in over-70s

By Benjamin Cowie, Director, WHO Collaborating Centre for Viral Hepatitis, The Peter Doherty Institute for Infection and Immunity
Brett Sutton, Adjunct Clinical Professor, Monash University
Christina Van Heer, PhD candidate at The School of Medicine, Dentistry and Health Sciences, The University of Melbourne
Suman Majumdar, Deputy Program Director, Health Security and Pandemic Preparedness, Burnet Institute

Analysis of Victoria’s winter COVID wave found Paxlovid and Lagevrio reduced the risk of hospitalisation and death. The results were better for Paxlovid, but not everyone can take it.

Read complete article

~	What lies behind the ‘golden opportunities’ of Malaysian Star media group's new tie with its mainland Chinese partner

~	“Urban form” and the housing crisis: Can streets and buildings make a neighbourhood more affordable?

~	The secret world of earthworms: meet the tiger worm and the nightcrawler

~	Curb Your Enthusiasm bows out after 24 years – or does it?

~	Venezuela: why Maduro is ramping up his attack on free speech

~	Not all young trans people want medical intervention – what is social transitioning, and how should schools handle it?

~	Man who caught virus from a monkey in a critical condition – B virus explained

~	The US is losing access to its bases in Niger − here’s why that’s a big deal

~	Foundations are using so many confusing words that few people can figure out what they’re doing

~	Exploding stars send out powerful bursts of energy − I’m leading a citizen scientist project to classify and learn about these bright flashes